Cytes Biotechnologies, a UB spin-off to promote research on cell models of human diseases

The initiative will mitigate the lack of isolated murine and human primary cells in international biomedical research.
The initiative will mitigate the lack of isolated murine and human primary cells in international biomedical research.
Research
(06/07/2015)

Researchers at the Faculty of Medicine of the UB have recently founded the spin-off Cytes Biotechnologies with the aim of developing and improving todayʼs inadequate protocols of isolation and differentiation of high quality human and murine cells in order to satisfy the needs of the international research community.

The initiative will mitigate the lack of isolated murine and human primary cells in international biomedical research.
The initiative will mitigate the lack of isolated murine and human primary cells in international biomedical research.
Research
06/07/2015

Researchers at the Faculty of Medicine of the UB have recently founded the spin-off Cytes Biotechnologies with the aim of developing and improving todayʼs inadequate protocols of isolation and differentiation of high quality human and murine cells in order to satisfy the needs of the international research community.

The activity of this biotech spin-off will be mainly focused on isolated liver cells which are in great demand in European and American research activity. Availability of murine and human isolated cells is crucial for biomedical research in vitro studies of toxicity, metabolism and cell viability, at research centres, universities and pharmaceutical companies, in order to design and develop new therapeutic strategies against common human diseases and rare diseases.  

Cytes Biotechnologies is based on the experience and entrepreneurship of professors Jordi Alberch, Josep Maria Canals and Raquel Martín, researchers in the Department of Cell Biology, Immunology and Neurosciences of the Faculty of Medicine, together with Martí Manyalich and Ricard Valero, from the Department of Surgery and Surgical Specializations. The Hammer Institute and the company QPS Hepatic Biosciences (USA) will collaborate in research and distribution studies.

The Bosch i Gimpera Foundation has supported the project through its Department of Business Creation. It has accompanied entrepreneurs in the definition of the business idea, the evaluation of the patentability strategy and the negotiation of the technology transfer contract, as also is helping the search for public and private funding.